300750 CONTEMPORARY AMPEREX TECHNOLOGY CO

EQS-News: Final results of the public takeover offer for Nexus AG: TA secures 94.95 % of all Nexus shares

EQS-News: Project Neptune Bidco GmbH / Key word(s): Tender Offer
Final results of the public takeover offer for Nexus AG: TA secures 94.95 % of all Nexus shares

08.01.2025 / 13:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


Final results of the public takeover offer for Nexus AG:
TA secures 94.95 % of all Nexus shares

 

8 January 2025

 

  • Subject to customary regulatory conditions, settlement of the Offer is currently expected in the first quarter of 2025
  • TA intends to pursue a delisting of Nexus from the stock exchange as soon as possible after the settlement of the Offer


Project Neptune Bidco GmbH, a holding company controlled by investment funds advised and managed by affiliates of TA Associates Management, L.P. (together “TA”) today published the final results of its voluntary public takeover offer (the “Offer”) for all shares of Nexus AG (“Nexus”, ISIN: DE0005220909) at the end of the additional acceptance period.

At the expiry of the additional acceptance period on 3 January 2025 at 24:00 hours, Frankfurt am Main local time, the Offer was accepted for 16,402,668 Nexus shares. This represents approximately
94.95 % of all Nexus shares, including approximately 26.9 % which TA had already secured through irrevocable undertakings with key Nexus shareholders.

Settlement of the Offer is subject to customary regulatory conditions, including antitrust and foreign investment control clearances. Subject to the fulfilment of these conditions, settlement of the Offer is currently expected to take place in the first quarter of 2025.

As soon as possible after the settlement of the Offer, TA intends to delist Nexus from the stock exchange. The Management Board of Nexus supports the intended delisting of Nexus in order to implement its long-term strategy outside of a stock market environment, subject to legal admissibility and careful review at the relevant time.

 

###

About TA Associates

TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five target industries – technology, healthcare, financial services, consumer and business services. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has over 160 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong.

Further information on TA can be found at .

 

About Nexus AG

Nexus AG develops and distributes software solutions for the international healthcare market. With the clinical information system (Nexus / KIS) and the integrated diagnostic modules, we now have a uniquely broad and interoperable product range that can cover almost all functional requirements of hospitals, psychiatric clinics, rehabilitation and diagnostic centers within our own product families. Nexus AG employs around 2,030 people, owns sites in nine European countries and supports customers in further 71 countries, in some cases via certified dealers. Due to the continuously growing demand for Nexus products, we have been able to build up a large customer base in recent years and regularly achieve increasing sales and results.

Further information on Nexus AG can be found at

 

Media Relations Contact – TA Associates

FGS Global

Tanja Dorr

975

 

Investor Relations Contact – Nexus AG

Investor Relations

Irmastraße 1

78166 Donaueschingen

 

Important Notice

This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares in Nexus AG. The terms of the takeover offer as well as other provisions relating to the takeover offer are set out in the offer document authorized for publication by the Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht). Investors and holders of shares in Nexus AG are strongly advised to read the offer document and all other documents relating to the takeover offer, as they contain important information.

The takeover offer is exclusively subject to the laws of the Federal Republic of Germany and certain applicable provisions of securities laws of the United States of America. Any agreement that is entered into as a result of accepting the takeover offer will be exclusively governed by the laws of the Federal Republic of Germany and is to be interpreted in accordance with such laws.

 



08.01.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: Project Neptune Bidco GmbH
c/o SCUR24 Holding GmbH Schwanthalerstraße 73
80336 Munich
Germany
EQS News ID: 2063741

 
End of News EQS News Service

2063741  08.01.2025 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2063741&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
08/01/2025

Underlying

300750CONTEMPORARY AMPEREX TECHNOLOGY CO

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONTEMPORARY AMPEREX TECHNOLOGY CO

 PRESS RELEASE

EQS-News: Dr. Greger & Collegen: Phishing - Die unsichtbare Falle – Si...

Emittent / Herausgeber: Dr. Greger & Collegen / Schlagwort(e): Rechtssache Dr. Greger & Collegen: Phishing - Die unsichtbare Falle – Sind Ihre Daten noch sicher? 09.01.2025 / 15:48 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Phishing - Die unsichtbare Falle – Sind Ihre Daten noch sicher? Auch 2025 schlagen Cyberkriminelle gnadenlos zu: Phishing-Angriffe sind gefährlicher denn je! Täuschend echte E-Mails, manipulierte Webseiten und perfide Tricks zielen darauf ab, Ihre Bankdaten, Passwörter und persönlichen Informationen zu stehlen...

 PRESS RELEASE

EQS-News: BioLizard Welcomes Arjan van Manen as Commercial Director an...

EQS-News: BioLizard nv / Key word(s): Personnel/Conference BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco 09.01.2025 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco   Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life sciences Meet BioLizard’s Arjan van Manen and CEO Liesbeth Ceelen at Biot...

 PRESS RELEASE

Laxxon Medical Announces Appointment of Two New Members to Board of Di...

Laxxon Medical Announces Appointment of Two New Members to Board of Directors New York, 01/09/2025 / 09:00, EST/EDT - EQS Newswire - Laxxon Medical Laxxon Medical, a leader in pharmaceutical drug delivery, announced today the appointment of new independent directors to its Board of Directors: Christof Bircher and Nneka Ukpai."We are excited to welcome both Christof Bircher and Nneka Ukpai to Laxxon's Board of Directors," said Helmut Kerschbaumer, Laxxon CEO and Chairman of the Board. "Both will bring extensive experience in business strategy, corporate finance and technology development, h...

 PRESS RELEASE

EQS-News: Bryan Garnier & Co berät PPM-Softwareanbieter collaboration ...

Emittent / Herausgeber: Bryan, Garnier & Co. / Schlagwort(e): Beteiligung/Unternehmensbeteiligung/Firmenübernahme Bryan Garnier & Co berät PPM-Softwareanbieter collaboration Factory (cplace) bei der Mehrheitsübernahme durch Level Equity / europäische Softwareunternehmen zunehmend im Fokus von US-Finanzinvestoren 09.01.2025 / 13:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Bryan Garnier & Co. berät PPM-Softwareanbieter collaboration Factory (cplace) bei Mehrheitsübernahme durch Level Equity / europäische Softwareunternehmen zune...

 PRESS RELEASE

EQS-News: Assessing Post-Cardiac Surgery Kidney Recovery Through PenKi...

Issuer: SphingoTec GmbH / Key word(s): Research Update/Scientific publication Assessing Post-Cardiac Surgery Kidney Recovery Through PenKid's Emerging Role in Renal Replacement Therapy Decisions 09.01.2025 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. Proenkephalin A 119-159 (penKid) demonstrates potential as a predictor for successful discontinuation of continuous renal replacement therapy (CRRT) in cardiac surgery patients. Study reveals significant differences in penKid levels between patients successfully and unsuccessfully l...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch